The tumor response rate in Figure 3B also shows that CAIR is significantly superior to CAIR minus anti-CD40/anti-CTLA-4, but there is not sufficient statistical power to determine whether it is superior to CAIR minus CPG/anti-CTLA-4 or CAIR minus CpG anti-CD40. The gene discussed is CD40; the disease is neoplasm.